|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
134,986 |
251,929 |
319,053 |
656,089 |
Total Sell Value |
$11,097,511 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
9 |
19 |
27 |
56 |
End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2017-03-07 |
4 |
AS |
$90.56 |
$452,800 |
D/D |
(5,000) |
46,510 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2017-03-06 |
4 |
AS |
$93.32 |
$214,916 |
D/D |
(2,303) |
20,761 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2017-03-06 |
4 |
AS |
$93.32 |
$139,793 |
D/D |
(1,498) |
78,962 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2017-03-03 |
4 |
D |
$93.95 |
$164,319 |
D/D |
(1,749) |
138,910 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2017-03-03 |
4 |
D |
$93.95 |
$164,319 |
D/D |
(1,749) |
51,510 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-03-03 |
4 |
D |
$93.95 |
$844,517 |
D/D |
(8,989) |
206,364 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2017-03-03 |
4 |
D |
$93.95 |
$214,488 |
D/D |
(2,283) |
23,064 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2017-03-03 |
4 |
D |
$93.95 |
$274,710 |
D/D |
(2,924) |
125,518 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2017-03-01 |
4 |
AS |
$94.50 |
$472,500 |
D/D |
(5,000) |
25,347 |
|
- |
|
Lawlis V Bryan |
Director |
|
2017-03-01 |
4 |
AS |
$95.00 |
$712,500 |
D/D |
(7,500) |
13,860 |
|
- |
|
Lawlis V Bryan |
Director |
|
2017-03-01 |
4 |
OE |
$17.33 |
$129,975 |
D/D |
7,500 |
21,360 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2017-02-28 |
4 |
AS |
$94.00 |
$2,820,000 |
D/D |
(30,000) |
30,347 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2017-02-28 |
4 |
OE |
$63.10 |
$1,893,000 |
D/D |
30,000 |
60,347 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
11,258 |
82,056 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2017-02-24 |
4 |
A |
$95.61 |
$1,139,396 |
D/D |
11,917 |
53,259 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2017-02-24 |
4 |
AS |
$87.99 |
$1,319,850 |
D/D |
(15,000) |
128,442 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2017-02-24 |
4 |
OE |
$26.49 |
$397,350 |
D/D |
15,000 |
143,442 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
14,564 |
128,442 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
44,671 |
215,353 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
11,917 |
140,659 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
12,247 |
30,347 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-26 |
4 |
AS |
$84.00 |
$420,000 |
D/D |
(5,000) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-26 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
175,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-25 |
4 |
AS |
$84.44 |
$422,200 |
D/D |
(5,000) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-25 |
4 |
OE |
$17.33 |
$86,650 |
D/D |
5,000 |
175,682 |
|
- |
|
1285 Records found
|
|
Page 37 of 52 |
|
|